← Back to patent-cliff list
CAS 1548618-47-8
methyl 4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate hydrobromide
Codes：PRAL-031
Application context (from source-drug indications)
外周T细胞淋巴瘤普拉曲沙T-细胞淋巴瘤普拉曲沙实体瘤普拉曲沙血液肿瘤普拉曲沙B-细胞淋巴瘤普拉曲沙皮肤T细胞淋巴瘤普拉曲沙
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 普拉曲沙Pralatrexate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
methyl 4-(2-methoxy-2-oxoethyl)benzoate→3-bromoprop-1-yne→methyl 4-(1-methoxy-1-oxopent-4-yn-2-yl)benzoate→6-(bromomethyl)pteridine-2,4-diamine→diethyl (4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoyl)-L-glutamate→methyl 4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate hydrobromide→4-(2-carboxy-1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid→sodium 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoate→(S)-diethyl 2-aminopentanedioate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.